RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · IEX Real-Time Price · USD
1.160
-0.040 (-3.33%)
At close: Jul 19, 2024, 4:00 PM
1.100
-0.060 (-5.17%)
Pre-market: Jul 22, 2024, 4:17 AM EDT
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.
RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RenovoRx, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Shaun R. Bagai |
Contact Details
Address: 333 W. Santa Clara Street, Suite 900 San Jose, California 95110 United States | |
| Phone | 408-800-2649 |
| Website | renovorx.com |
Stock Details
| Ticker Symbol | RNXT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001574094 |
| CUSIP Number | 75989R107 |
| ISIN Number | US75989R1077 |
| Employer ID | 27-1448452 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaun R. Bagai | Chief Executive Officer and Director |
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board and Chief Medical Officer |
| Ronald B. Kocak CPA, CGMA | Vice President, Controller and Principal Accounting Officer |
| Leesa Gentry | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 7, 2024 | 8-K | Current Report |
| May 10, 2024 | EFFECT | Notice of Effectiveness |
| May 10, 2024 | EFFECT | Notice of Effectiveness |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 424B3 | Prospectus |
| May 10, 2024 | 424B3 | Prospectus |
| May 3, 2024 | 8-K | Current Report |
| May 1, 2024 | UPLOAD | Filing |
| Apr 30, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 26, 2024 | S-3 | Registration statement under Securities Act of 1933 |